AGM Statement and Directorate Change

This announcement contains inside information

Quantum Pharma Plc

('Quantum' or the 'Company')

AGM Statement and Directorate Change

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, will hold its Annual General Meeting in Newcastle later today.

At the meeting, Quantum's Chairman, John Clarke, will make the following statement:

"Trading in the first half of the current financial year has been in line with management's expectations.

"Our Specials Division continues to be well placed in the market and has had a sound first half performance. We were pleased to extend our contract with AAH Pharmaceuticals, the UK's leading wholesaler and distributor of pharmaceutical and healthcare products. 

"We are encouraged by the results of our programme of actions in our Niche Pharmaceuticals Division and have increased confidence in the processes and operating model. Importantly, the product launches during the year have all arrived largely in line with our expectations. We have announced product licences for two new strengths of Vitamin D capsules and the launch of Ergocalciferol 50,000 IU capsules, the first unlicensed to licensed development for this product in the UK, by way of a 'cease and desist' notice. Recently we announced the launch of the Mucodis® Dermal Spray, part of the Mucodis® range, which treats the unpleasant conditions in the mucosal membranes caused by the treatment of cancer. This is the third product launched in the Mucodis® range and we expect to announce a number of further product launches across the remainder of this financial year.

"In Medical Adherence, we have received Class 1 medical device status for Biodose Connect® which is now ready for patient use and we can start to implement our commercialisation strategy for this device.

"As previously indicated, our performance for the current financial year will be second half weighted as we bring our product pipeline to the market. As this is progressing well, we are positive about the Company's outlook."

Directorate Change

Andrew Scaife, the Chief Executive Officer, has tendered his resignation as a Director of the Company for family reasons. The Board has commenced a formal search process to secure his replacement as soon as possible. Andrew has agreed to remain as Chief Executive Officer until such time as that appointment is confirmed and to facilitate a smooth handover.

Quantum's Chairman, John Clarke, said: "Andrew has made a significant contribution to the Group during the past seven years and has been instrumental to the Group's growth and strategic direction, and to its admission to AIM in 2014. On behalf of the Board of directors of the Company, I would like to thank Andrew for his contribution and wish him the best for his future career."

- Ends -

For further information:

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets through our Specials and Medication Adherence divisions to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.